^
Association details:
| Biomarker: | BRCA2 mutation + TMB-L |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors
Published date:
05/07/2021
Excerpt:
Patients with low TMB BRCA2 altered tumors had comparable OS with patients with high TMB tumors (median [IQR] OS, 44.0 [10.0-67.0] months vs 41.0 [13.0-80.0] months), and both groups had better OS than patients with low TMB WT BRCA2 tumors (median [IQR] OS, 16.0 [6.0-57.0] months; P < .001) (Figure 2C).
DOI:
10.1001/jamanetworkopen.2021.7728
